During a recent visit to Gothenburg, Jacob Wallenberg, Chairman of the Confederation of Swedish Enterprises and Investor AB, toured the new CCRM Nordic facilities currently under construction at GoCo Health Innovation City. The visit underscored a message he has repeatedly emphasized in the national debate: Sweden cannot take its success for granted.
To remain competitive in an increasingly challenging global landscape, Sweden must renew its hunger for growth, invest in research and innovation and build strategic technology infrastructure. Without decisive and sustained action, even leading life science nations risk losing momentum.
A national asset for advanced therapies
CCRM Nordic is a national infrastructure dedicated to accelerating the commercialization of advanced therapy medicinal products (ATMPs) and associated technologies. By combining specialized manufacturing and development capabilities with active ecosystem building, CCRM Nordic advances national strategies by enabling innovative projects and companies to scale faster, more reliably and with lower risk.
During the visit, Jacob Wallenberg highlighted the broader strategic significance of initiatives such as CCRM Nordic:
“If Sweden is to remain competitive, we must invest in the capabilities that turn research excellence into industrial and clinical impact. CCRM Nordic is a strong example of the kind of long-term, strategic infrastructure that helps secure Sweden’s position in a highly competitive global landscape.”
Enabled by strong public–private support from government and industry, CCRM Nordic’s soon-to-open 3,000 m² purpose-built facility represents a major step forward. Designed to support the full journey from research to scalable manufacturing and clinical readiness, it will help translate scientific breakthroughs into real treatments for patients.
The new facility enables CCRM Nordic to bring together multidisciplinary expertise across areas such as immuno-oncology, pluripotent stem cells and viral vectors, combined with advanced analytical capabilities, creating a platform built for both innovation and industrialization.
Why this matters for Sweden
As a not-for-profit, public–private-partnership supported by the Swedish government, CCRM Nordic has a clear mission to strengthen Sweden’s and Europe’s competitiveness in advanced therapies. CCRM Nordic’s capabilities are central to securing Sweden’s long-term competitiveness and resilience in advanced therapies, for example, through:
- Strategic technology investment
Developing critical advanced therapy capabilities that are essential for future healthcare delivery and industrial competitiveness.
- Innovation and production infrastructure
Bridging the gap between research, GMP manufacturing and clinical implementation to accelerate translation and reduce risk.
- Cross-sector collaboration
Bringing together government, academia, industry and investors around shared, long-term objectives.
Investing in the future, together
Working alongside Jacob Wallenberg and partners across research, industry and investment, CCRM Nordic is building the infrastructure, capabilities and collaborations needed to turn world-class research into lasting societal and economic impact.
As CCRM Nordic’s new facilities take shape, they stand as a tangible response to Jacob Wallenberg’s call to action: success cannot be taken for granted, it must be continuously earned.
Join us in strengthening Sweden’s competitiveness in advanced therapies
Whether you are a researcher, innovator, investor or industry partner, CCRM Nordic is building the capabilities and collaborations needed to turn scientific excellence into real patient impact.
Explore partnership opportunities with CCRM Nordic: https://ccrmnordic.se/